Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
EOLS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
EOLS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Distribution |
| Market Cap | $416M | $91.09B |
| Revenue (TTM) | $301M | $397.96B |
| Net Income (TTM) | $-43M | $4.34B |
| Gross Margin | 65.7% | 3.4% |
| Operating Margin | -9.6% | 1.3% |
| Forward P/E | — | 19.1x |
| Total Debt | $155M | $7.39B |
| Cash & Equiv. | $54M | $5.69B |
EOLS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 100 | 138.3 | +38.3% |
| McKesson Corporation (MCK) | 100 | 468.7 | +368.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EOLS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
In this particular matchup, EOLS is outpaced on most metrics by others in the set.
MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 17 yrs, beta 0.04, yield 0.4%
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 351.9% 10Y total return vs EOLS's -45.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs EOLS's 11.6% | |
| Quality / Margins | 1.1% margin vs EOLS's -14.4% | |
| Stability / Safety | Beta 0.04 vs EOLS's 1.27 | |
| Dividends | 0.4% yield; 17-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +5.0% vs EOLS's -45.6% | |
| Efficiency (ROA) | 5.3% ROA vs EOLS's -19.4%, ROIC 5.4% vs -44.5% |
EOLS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EOLS vs MCK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MCK leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $398.0B annually — 1320.4x EOLS's $301M. MCK is the more profitable business, keeping 1.1% of every revenue dollar as net income compared to EOLS's -14.4%. On growth, MCK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $301M | $398.0B |
| EBITDAEarnings before interest/tax | -$21M | $5.8B |
| Net IncomeAfter-tax profit | -$43M | $4.3B |
| Free Cash FlowCash after capex | -$41M | $10.1B |
| Gross MarginGross profit ÷ Revenue | +65.7% | +3.4% |
| Operating MarginEBIT ÷ Revenue | -9.6% | +1.3% |
| Net MarginNet income ÷ Revenue | -14.4% | +1.1% |
| FCF MarginFCF ÷ Revenue | -13.7% | +2.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.2% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +46.7% | +38.2% |
Valuation Metrics
Evenly matched — EOLS and MCK each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $416M | $91.1B |
| Enterprise ValueMkt cap + debt − cash | $517M | $92.8B |
| Trailing P/EPrice ÷ TTM EPS | -7.90x | 28.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.06x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.74x |
| EV / EBITDAEnterprise value multiple | — | 18.53x |
| Price / SalesMarket cap ÷ Revenue | 1.40x | 0.25x |
| Price / BookPrice ÷ Book value/share | — | — |
| Price / FCFMarket cap ÷ FCF | — | 17.43x |
Profitability & Efficiency
MCK leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs EOLS's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | — |
| ROA (TTM)Return on assets | -19.4% | +5.3% |
| ROICReturn on invested capital | -44.5% | +5.4% |
| ROCEReturn on capital employed | -23.5% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $101M | $1.7B |
| Cash & Equiv.Liquid assets | $54M | $5.7B |
| Total DebtShort + long-term debt | $155M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | -1.92x | 25.04x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $40,840 today (with dividends reinvested), compared to $7,290 for EOLS. Over the past 12 months, MCK leads with a +5.0% total return vs EOLS's -45.6%. The 3-year compound annual growth rate (CAGR) favors MCK at 26.8% vs EOLS's -10.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -6.0% | -9.6% |
| 1-Year ReturnPast 12 months | -45.6% | +5.0% |
| 3-Year ReturnCumulative with dividends | -29.2% | +104.0% |
| 5-Year ReturnCumulative with dividends | -27.1% | +308.4% |
| 10-Year ReturnCumulative with dividends | -45.0% | +351.9% |
| CAGR (3Y)Annualised 3-year return | -10.9% | +26.8% |
Risk & Volatility
MCK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than EOLS's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 74.4% from its 52-week high vs EOLS's 52.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 0.04x |
| 52-Week HighHighest price in past year | $12.16 | $999.00 |
| 52-Week LowLowest price in past year | $3.86 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +52.0% | +74.4% |
| RSI (14)Momentum oscillator 0–100 | 77.6 | 25.8 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 737K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EOLS as "Buy" and MCK as "Buy". Consensus price targets imply 137.3% upside for EOLS (target: $15) vs 35.3% for MCK (target: $1007). MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $1006.50 |
| # AnalystsCovering analysts | 13 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 17 |
| Dividend / ShareAnnual DPS | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.5% |
MCK leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
EOLS vs MCK: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is EOLS or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus 11. 6% for Evolus, Inc. (EOLS). McKesson Corporation (MCK) offers the better valuation at 28. 9x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Evolus, Inc. (EOLS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EOLS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.
4%, compared to -27. 1% for Evolus, Inc. (EOLS). Over 10 years, the gap is even starker: MCK returned +351. 9% versus EOLS's -45. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EOLS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Evolus, Inc. 's 1. 27β — meaning EOLS is approximately 2848% more volatile than MCK relative to the S&P 500.
04Which is growing faster — EOLS or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus 11. 6% for Evolus, Inc. (EOLS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to 1. 2% for Evolus, Inc.. Over a 3-year CAGR, EOLS leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EOLS or MCK?
McKesson Corporation (MCK) is the more profitable company, earning 0.
9% net margin versus -17. 4% for Evolus, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -12. 7% for EOLS. At the gross margin level — before operating expenses — EOLS leads at 64. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is EOLS or MCK more undervalued right now?
Analyst consensus price targets imply the most upside for EOLS: 137.
3% to $15. 00.
07Which pays a better dividend — EOLS or MCK?
In this comparison, MCK (0.
4% yield) pays a dividend. EOLS does not pay a meaningful dividend and should not be held primarily for income.
08Is EOLS or MCK better for a retirement portfolio?
For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
04), +351. 9% 10Y return). Both have compounded well over 10 years (MCK: +351. 9%, EOLS: -45. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between EOLS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EOLS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.